Retinal neuroprotective effects of flibanserin, an FDA-Approved dual serotonin receptor agonist-antagonist

Agriculture & Biology

• serotonin receptors 66%
• neuroprotective effect 65%
• agonists 44%
• antagonists 41%
• mice 27%
• retinal diseases 23%
• retinal degeneration 12%
• injection 10%
• electroretinography 10%
• tomography 10%
• gene expression 9%
• dosage 8%
• albino 7%
• animal models 6%
• cats 6%
• oxidative stress 6%
• receptors 5%
• drugs 5%
• methodology 2%

Medicine & Life Sciences

• flibanserin 89%
• Serotonin Receptor Agonists 63%
• Serotonin Antagonists 61%
• Neuroprotective Agents 48%
• N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide 9%
• Serotonin 5-HT1 Receptor Antagonists 9%
• Light 9%
• Neuroprotection 6%
• Knockout Mice 5%
• Drug Repositioning 4%
• Serotonin 5-HT2 Receptor Antagonists 4%
• Serotonin 5-HT1 Receptor Agonists 4%
• Electroretinography 4%
• Receptor, Serotonin, 5-HT1A 3%
• Retinal Degeneration 3%
• Gene Expression 3%
• Injections 3%
• Optical Coherence Tomography 3%
• Cats 2%
• Oxidative Stress 2%
• Therapeutics 1%

Chemical Compounds

• Flibanserin 100%
• Neuroprotective 60%
• Retinal 54%
• Serotonin 52%
• Serotonin 1A Antagonist 13%
• Serotonin 1A Agonist 6%
• Serotonin 2A Antagonist 6%
• Intraperitoneal 5%
• Oxidative Stress 3%
• Dose 3%
• Drug 2%